NCT06539806 Clinical Study Evaluating the Effect of Losartan
| NCT ID | NCT06539806 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Tanta University |
| Condition | Pancreatic Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 90 participants |
| Start Date | 2024-07-20 |
| Primary Completion | 2026-08-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 90 participants in total. It began in 2024-07-20 with a primary completion date of 2026-08-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The pancreas is two organs packaged into one. The islets of Langerhans serve critical endocrine functions, and the exocrine portion is a major source of enzymes that are essential for digestion. Pancreatic cancer (PC) is more commonly referred to as pancreatic infiltrating ductal adenocarcinoma in addition to being the second leading cause of cancer death in the United States, after lung cancer in 2020. Whereas pancreatic cancer is the seventh cause of death from cancer in Asia in 2020. Although it is substantially less common than the other malignancies, pancreatic carcinoma is near the top of the list of killers because it is a highly aggressive carry.
Eligibility Criteria
Inclusion Criteria: * Male and female pancreatic cancer patients aged ≥ 50 years old. * Hypertensive patient with BP ≥ 140/90 mm Hg. * Histologically confirmed metastatic pancreatic adenocarcinoma; or locally advanced pancreatic cancer patients. * All included patients must sign an informed consent Exclusion Criteria: * Patients with serious concomitant systemic disorders as significant cardiac, renal, hepatic, or pulmonary morbidity. * Pregnant or lactating women and women of childbearing potential. * Patients received prior systemic fluoropyrimidine therapy within the past 10 years. * Prior un-anticipated severe reaction to fluoropyrimidine therapy, or known hypersensitivity to 5-fluorouracil, irinotecan, oxaliplatin, losartan, or any monoclonal antibody. * Patients with an active, known, or suspected autoimmune disease such as psoriasis. * Patients with a known positive test for hepatitis B virus surface antigen (HBV s Ag) or hepatitis C virus (HCV antibody) and patients with a known history of testing positive for (HIV) or known acquired immunodeficiency syndrome (AIDS). * Patients received a live vaccine or live attenuated vaccines as intranasal influenza vaccines within 30 days of the planned start of study therapy.
Contact & Investigator
Osama Mohamed Hassan, Professor
STUDY DIRECTOR
Clinical Pharmacy Department Faculty of Pharmacy, Tanta University
Frequently Asked Questions
Who can join the NCT06539806 clinical trial?
This trial is open to participants of all sexes, aged 50 Years or older, up to 85 Years, studying Pancreatic Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06539806 currently recruiting?
Yes, NCT06539806 is actively recruiting participants. Contact the research team at drmona.abdo14@gmail.com for enrollment information.
Where is the NCT06539806 trial being conducted?
This trial is being conducted at Tanta, Egypt.
Who is sponsoring the NCT06539806 clinical trial?
NCT06539806 is sponsored by Tanta University. The principal investigator is Osama Mohamed Hassan, Professor at Clinical Pharmacy Department Faculty of Pharmacy, Tanta University. The trial plans to enroll 90 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.